Totality of trials data confirm Tamiflu reduces length of symptoms, complications, and hospital admissions from influenza

30 enero 2015

The most thorough analysis of oseltamivir (marketed as Tamiflu) data to date, including all available published and unpublished randomised treatment trials of adults, suggests that the antiviral drug shortens the duration of flu symptoms by about a day, compared to placebo, in adults with laboratory-confirmed influenza.